F K Gorus
Overview
Explore the profile of F K Gorus including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
72
Citations
1084
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Brackeva B, De Punt V, Kramer G, Costa O, Verhaeghen K, Stange G, et al.
J Proteomics
. 2015 Feb;
117:156-67.
PMID: 25638021
Biological Significance: Our bottom-up LC-MS/MS proteomics represents a pragmatic approach to identify protein-type biomarkers of pancreatic beta cell injury. UCHL1 successfully passed sequential validation steps of beta cell-selectivity, antigenicity and...
2.
Lauria A, Barker A, Schloot N, Hosszufalusi N, Ludvigsson J, Mathieu C, et al.
Eur J Endocrinol
. 2014 Nov;
172(2):107-13.
PMID: 25378371
Objective: Body weight-related insulin resistance probably plays a role in progression to type 1 diabetes, but has an uncertain impact following diagnosis. In this study, we investigated whether BMI measured...
3.
Barker A, Lauria A, Schloot N, Hosszufalusi N, Ludvigsson J, Mathieu C, et al.
Diabetes Obes Metab
. 2013 Oct;
16(3):262-7.
PMID: 24118704
Aims: C-peptide secretion is currently the only available clinical biomarker to measure residual β-cell function in type 1 diabetes. However, the natural history of C-peptide decline after diagnosis can vary...
4.
Mbunwe E, Van der Auwera B, Weets I, Van Crombrugge P, Crenier L, Coeckelberghs M, et al.
Diabetologia
. 2013 May;
56(9):1964-70.
PMID: 23712485
Aims/hypothesis: Secondary type 1 diabetes prevention trials require selection of participants with impending diabetes. HLA-A and -B alleles have been reported to promote disease progression. We investigated whether typing for...
5.
Gorus F, Balti E, Vermeulen I, DeMeester S, van Dalem A, Costa O, et al.
Clin Exp Immunol
. 2012 Dec;
171(1):82-90.
PMID: 23199327
In first-degree relatives of type 1 diabetic patients, we investigated whether diabetes risk assessment solely based on insulinoma antigen 2 (IA-2) and zinc transporter 8 (ZnT8) antibody status (IA-2A, respectively,...
6.
Huurman V, van der Torren C, Gillard P, Hilbrands R, van der Meer-Prins E, Duinkerken G, et al.
Clin Exp Immunol
. 2012 Jul;
169(2):190-8.
PMID: 22774994
Transplantation of isolated islet of Langerhans cells has great potential as a cure for type 1 diabetes but continuous immune suppressive therapy often causes considerable side effects. Tapering of immunosuppression...
7.
Vermeulen I, Weets I, Costa O, Asanghanwa M, Verhaeghen K, Decochez K, et al.
Diabetologia
. 2011 Nov;
55(2):413-20.
PMID: 22095238
Aims/hypothesis: The appearance of autoantibodies (Abs) before diabetes onset has mainly been studied in young children. However, most patients develop type 1 diabetes after the age of 15 years. In...
8.
De Grijse J, Asanghanwa M, Nouthe B, Albrecher N, Goubert P, Vermeulen I, et al.
Diabetologia
. 2010 Jan;
53(3):517-24.
PMID: 20091020
Aims/hypothesis: We investigated whether screening for insulinoma-associated protein (IA-2) beta (IA-2beta) autoantibodies (IA-2betaA) and zinc transporter-8 (ZnT8) autoantibodies (ZnT8A) improves identification of first-degree relatives of type 1 diabetic patients with...
9.
Vandemeulebroucke E, Keymeulen B, Decochez K, Weets I, De Block C, Fery F, et al.
Diabetologia
. 2009 Nov;
53(1):36-44.
PMID: 19898832
Aims/hypothesis: The aim of the study was to investigate the use of hyperglycaemic clamp tests to identify individuals who will develop diabetes among insulinoma-associated protein-2 antibody (IA-2A)-positive first-degree relatives (IA-2A(+)...
10.
Vandemeulebroucke E, Gorus F, Decochez K, Weets I, Keymeulen B, De Block C, et al.
Diabetes Metab
. 2009 Aug;
35(4):319-27.
PMID: 19647467
Aims: We examined whether parenteral regular insulin can prevent diabetes in IA-2 antibody-positive (IA-2A+) relatives of type 1 diabetic patients, using a trial protocol that differed substantially from that of...